AIDS and the lung in a changing world

Thorax

Volumn 56, Issue 6, 2001, Pages 423-426

  Mayaud, C ^a   Cadranel, J ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EDITORIAL; FOLLOW UP; HUMAN; INFECTION PREVENTION; LUNG INFECTION; LUNG INSUFFICIENCY; LUNG SARCOIDOSIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INCIDENCE; LUNG DISEASES; PREVALENCE; RESPIRATORY TRACT INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WORLD HEALTH;

EID: 0035016659     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.56.6.423     Document Type: Editorial

References (68)

1. Pulmonary infectious complications of HIV infection
2. Non infectious pulmonary complications of infection with the HIV
3. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS cohort study
4. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
5. Effect of HAART on natural history of AIDS-related opportunistic disorders
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. AIDS across Europe, 1994-98: The EuroSIDA study
8. Respiratory disease trends in the pulmonary complications of HIV infection study cohort
9. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers
10. HIV-associated primary pulmonary hypertension
11. Lung carcinoma in 36 patients with human immunodeficiency virus infection
12. Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: A new clinical entity?
13. Primary pulmonary AIDS-related lymphoma
14. Accelerated obstructive pulmonary disease in HIV-infected patients with bronchiectasis
15. Pulmonary complications of the AIDS
16. Pulmonary diseases in patients infected with the HIV in Zimbabwe, Central Africa
17. The mortality and pathology of HIV infection in a west African city
18. Aetiology, outcome and risk factors for mortality among adults with acute pneumonia in Kenya
19. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi
20. Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda
21. Pneumocystis carinii pneumonia in Zimbabwe
22. Impact of opportunistic disease on survival in HIV-infected patients
23. Tuberculosis in AIDS: Past or new problems?
24. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
25. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection
26. A controlled trial of trimethroprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
27. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfamides or both
28. Effects of mutations in Pneumocystis carinii dihydropteorate synthase gene on outcome of AIDS-associated P carinii pneumonia
29. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients
30. P carinii dihydropteorate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use
31. Isoniazid prophylaxis for tuberculosis in HIV-infection: A meta-analysis of randomized controlled trials
32. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost effectiveness analysis
33. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: An operational assessment at a voluntary counselling and testing center
34. Risk factors for rifampin mono-resistant tuberculosis
35. Randomized trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-infection
36. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1 infected individuals: A randomized trial
37. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: A controlled clinical trial
38. Pneumonia in HIV-infected patients: A case-control survey of factors involved in risk and prevention
39. Observational studies of pneumococcal polysaccharide vaccine effectiveness among HIV-infected adults, USA, 1990-1998
40. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
41. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya
42. 23-valent pneumococcal polysaccharide vaccine in HIV-1 Ugandan adults: Double-blind, randomized and placebo controlled trial
43. Mechanisms of failure of pneumococcal polysaccharide vaccine in HIV-infection and alternate approaches to prophylaxis
44. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
45. Community acquired bacteremia in HIV-positive patients: Protective benefit of cotrimoxazole
46. Risk factor for community-acquired pneumonia among persons infected with human immunodeficiency virus
47. Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia and death in persons with AIDS
48. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Côte d'Ivoire: A randomized trial
49. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: A randomized controlled trial
50. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era
51. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
52. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy
53. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
54. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
55. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
56. Pre-AIDS mortality in HIV-infected individuals in England, Wales and Northern Ireland 1982-1996
57. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
58. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia
59. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
60. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
61. Subacute hypersensitivity pneumonitis in an HIV infected patient receiving antiretroviral therapy
62. Sympomatic hyperlactataemia: An emerging complication of antiretroviral therapy
63. Hypersensitivity reactions during therapy with abacavir: Analysis of 636 cases for clinical presentation and risk factors
64. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction
65. Tuberculosis in patients with human immunodeficiency virus infection
66. The treatment of tuberculosis in HIV-infected persons
67. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis